

(ii) a polypeptide consisting of at least 6 contiguous amino acids of sequence of pre-S1 of hepatitis B virus (HBV),
wherein the fusion polypeptide induces antibody that recognizes pre-S1 of HBV.

36. (New) A fusion polypeptide according to claim 35 which comprises at least 20 contiguous amino acids of the sequence of pre-S1.

37. (New) A fusion polypeptide according to claim 35 which comprises amino acids 21 to 47 of pre-S1.

38. (New) A fusion polypeptide according to claim 35 wherein the polypeptide consisting of at least 6 contiguous amino acids of sequence of tetanus toxin fragment C and the polypeptide consisting of at least 6 contiguous amino acids of sequence of pre-S1 of HBV are joined by a hinge linker.

39. (New) A fusion polypeptide according to claim 35 which comprises at least 100 contiguous amino acids of the sequence of tetanus toxin fragment C.

40. (New) A fusion polypeptide according to claim 35 which comprises full length fragment C.

41. (New) An immunogenic composition comprising a pharmaceutically acceptable carrier or diluent and a fusion polypeptide comprising
(i) a polypeptide consisting of at least 6 contiguous amino acids of sequence of tetanus toxin fragment C, fused to